Recent articles
These 2 Neuroscience Stocks Have Tanked as Much as 33% Since September 1. Are They Buys?
Two healthcare stocks, two plunging stock prices, and two unique scenarios heading into the end of 2019.
2 Trends in Wind Power That Investors Need to Know About
The American wind power industry has reached an important level of maturity, but that changes the game for investors.
Here's Why Liquid Biopsy Stocks Fell as Much as 39.2% in September
Is Wall Street's initial excitement giving way to more realistic expectations?
Why These Lithium Stocks Rose as Much as 12.8% in September
It's a small correction, because each of these three stocks is down at least 13% since the beginning of the year due to fears of a supply glut.
Here's Why Amyris Rose 10.5% Before Slipping Into Negative Territory Today
The company filed its annual report for 2018 and gave a brief update on first-half 2019 operations.
Here's Why Minerva Neurosciences Fell Over 28% Today
A cyberattack resulted in a clinical trial delay. Really.
2 Growth Stocks for In-the-Know Investors
These two healthcare businesses are capturing formidable growth opportunities by executing in their overlooked niches.
2 Top Stocks That Aren't on Wall Street's Radar
A recent IPO and a small fertilizer producer appear to have been overlooked by Mr. Market, but individual investors might want to keep an eye on both.
This Biotech Leans on 1 Customer for 56% of Revenue, but There's a Catch
Depending on one customer for too much revenue is generally a red flag, but the intentional growth strategy of Personalis is worth paying closer attention to.
2 Dividend Stocks Perfect for Retirees
These two companies generate plenty of cash flow to sustain -- and grow -- their dividend payouts for years to come.
Are the Shorts Right About This Clinical-Stage Pharma?
Investors walked away from UroGen Pharma after an article was published by a short-seller, but clinical results appear to favor the company.
Is This $5 Billion Biotech IPO a Buy?
10X Genomics is growing revenue at a healthy clip, but a series of patent-infringement suits are hanging over the lab-hardware business.
Here's Why Lannett Company Stock Is Tumbling Today
The generic drug specialist raised money through a debt offering that might be a little more complicated than necessary.
Here's Why Clovis Oncology Fell as Much as 13.5% Today
Wall Street is questioning the value and purpose of a recent deal.
The Single Most Important Thing for Fluidigm Shareholders to Watch
The volatile stock still has potential, but investors need the proper perspective for the slow-growing hardware business.
Can iRhythm Technologies Have Its Growth and Make a Profit Too?
Management has expanded selling, general, and administrative expenses in lockstep with gross profit increases. The aggressive strategy has a cost.
Here's Why McDermott International Is Plunging Today
The engineering and construction company is working with an outside consulting firm on a turnaround strategy. Those tend to be painful.
Here's Why Translate Bio Dropped Today
The company announced a stock offering to raise cash, but today's drop could've been much worse.
Here's Why PTC Therapeutics Fell as Much as 12.5% Today
The business is raising cash through two offerings: one of debt and one of common stock.
Here's Why Bloom Energy Is Tumbling Today
Investors continue to sour on the solid oxide fuel cell developer.